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CD4(+) but not CD8(+) lymphocytes in peripheral blood of 
lung cancer patients (p<0,05). We have also observed higher 
levels of the T-bet(+) and ROR-γt(+) CD4(+) lymphocytes with 
decreased level of the FoXP3 (+) CD4(+) cells (p<0,05), and 
accumulation of GATA-3(+) CD4(+) lymphocytes specific for 
TH2 immune response (p<0,05).  
 
 
Conclusions: PD-1 and CTLA-4 act as negative regulators of T 
cell activation (checkpoint antigens) and their enhanced 
expression may results from immunological overstimulation 
which may also be the cause of decreased percentage of 
regulatory T cells observed 12 weeks following SRBT. SBRT 
changes immune response towards Th2 phenotype. 
Correlation of these observations with the results of the 
treatment may make future trials, looking for factors 
predictive for response to immunotherapy, possible. 
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Purpose/Objective: Small-cell lung cancer (SCLC) has several 
characteristics that distinguish it from other lung cancers 
types, mainly its high propensity to disseminate and most 
particularly the high risk of brain failure. The incidence of 
brain metastases (BM) in SCLC is estimated at 10–14% at the 
time of initial diagnosis. Prophylactic cranial irradiation (PCI) 
has proven its efficacy, not only in terms of brain failure but 
also in terms of survival in patients with non metastatic and 
metastatic disease. More recent trials have also addressed 
the issue of the possible neurotoxicity of PCI. This study 
attempted to delineate the distribution of brain metastases 
with relation to the hippocampus for the purpose of exploring 
the viability of hippocampal sparing radiotherapy to 
potentially reduce neurocognitive deficits from radiation 
Materials and Methods: The pre-radiotherapy T1-weighted, 
contrast-enhanced axial MR images of 20 patients who had 
brain metastases of small-cell lung cancer in first-line 
chemotherapy between 2009 and 2014 were studied. Axial 
images were used to contour the hippocampus as well as 
each metastasis. The anatomic boundaries of the 
hippocampus were identified according to the RTOG 0933. 
We contoured brain metastases as well as hippocampi with  
5-, 10-, and 15-mm expansion envelopes. 
Results: Of 193 identified metastases, 3.1% (n =6) were 
located within 5 mm of the hippocampus, 2.1% (n=4) between 
5 and 10 mm and 3.1% (n=6) between 10 and 15 mm. Then, 
8.3% of our patients presented hippocampal or 
peri/hippocampal metastasis. Ninety-two percent of 
metastases were located greater than 15 mm from the 
hippocampus (n =177). 
Conclusions: In our study, 8.3% of patients had metastases 15 
mm around the hippocampus, or less. Hence, a 15-mm 
margin around the hippocampus for conformal avoidance 
whole brain radiotherapy represents an unacceptable risk of 
disease progression after hippocampal avoidance during 
prophylactic whole-brain radiotherapy for small cell lung 
cancer. 
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Purpose/Objective: Severe radiation induced esophagitis is a 
frequent side-effect of concurrent accelerated chemo-
radiation for small cell lung cancer (SCLC).  
Pre-treatment predictive models can facilitate identifying 
high-risk patients to provide intensive nutritional support or 
prophylactic placement of a naso-gastric feeding tube. 
Materials and Methods: We analyzed 240 consecutive 
patients with stage I-III SCLC from our prospective database, 
referred between December 2004 and March 2014 for 
concurrent platinum-etoposide and accelerated radiotherapy. 
All patients were FDG-PET-staged and received 45 Gy in 1.5 
Gy fractions twice daily to the tumor and PET-positive or 
pathologically proven lymph nodes. 97% of patients received 
concurrent chemo-radiation as planned, the remaining 3% of 
patients were treated sequentially. A total of 47 patients 
(20%) experienced dysphagia grade ≥3 (CTCAE 4.0). 
A set of clinical (e.g. cT-stage, cN-stage, age, gender, WHO-
PS, smoking status,...), biochemical (platelet count, 
hemoglobin and LDH at diagnosis) and radiotherapy planning 
parameters (e.g. mean (Dmean) and maximal dose (Dmax) to 
the esophagus, GTV,...) of potential relevance for esophagitis 
was retrieved for each patient.  
We developed three distinct prediction models for dysphagia 
grade ≥3:  
Model 1: based on classical clinical/ biochemical factors only. 
Model 2: based on the same set of parameters as Model 1, 
but replacing the classical nodal parameters (cN-stage, cN3-
stage) investigated for model 1 by the number of treated 
nodal stations with close proximity to the esophagus (``High 
Risk stations``: 1L, 1R, 3P, 4L, 7, 8 and 9). 
Model 3: based on both classical clinical/ biochemical and 
planning parameters.  
A bootstrap approach was used to assess how many variables 
should be included in the models: 2 or 3 variables for model 
1, 3 for model 2 and 4 for model 3. 
For each model individually the strongest combination of 
parameters from the data-set was composed using a 
backward selection procedure based on Akaike's Information 
Criterion (AIC). 
Results: For Model 1 the following variables were statistically 
significant: cT4 (yes/no), platelet count and gender. cN-stage 
